Sionna Net Income Per E B T from 2010 to 2026
| SION Stock | 36.11 0.86 2.44% |
Net Income Per E B T | First Reported 2010-12-31 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 0.0 |
Check Sionna Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sionna Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 9.9 M, Interest Income of 9.9 M or Depreciation And Amortization of 503.4 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Sionna financial statements analysis is a perfect complement when working with Sionna Therapeutics Valuation or Volatility modules.
Sionna | Net Income Per E B T | Build AI portfolio with Sionna Stock |
Pair Trading with Sionna Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sionna Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sionna Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Sionna Stock
Moving against Sionna Stock
| 0.58 | KRRO | Frequency Therapeutics | PairCorr |
| 0.57 | EVGN | Evogene | PairCorr |
| 0.44 | JUMP | Leveljump Healthcare Corp | PairCorr |
| 0.44 | QSI | QuantumSi | PairCorr |
| 0.33 | IMRN | Immuron Ltd ADR | PairCorr |
The ability to find closely correlated positions to Sionna Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sionna Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sionna Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sionna Therapeutics Common to buy it.
The correlation of Sionna Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sionna Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sionna Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sionna Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Sionna Therapeutics Correlation against competitors. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Will Biotechnology sector continue expanding? Could Sionna diversify its offerings? Factors like these will boost the valuation of Sionna Therapeutics. If investors know Sionna will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Sionna Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Sionna Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Sionna Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Sionna Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Sionna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sionna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Sionna Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.